Salarius Pharmaceuticals, Inc. (SLRX) Reports Q2 Loss of $1.43
Tweet
Share
E-mailGet Alerts SLRX Hot Sheet
Join SI Premium – FREE
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) reported Q2 EPS of ($1.43).
For earnings history and earnings-related data on Salarius Pharmaceuticals, Inc. (SLRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
- UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
